Regeneron Updates Outlook

2023 Guidance Prior Updated GAAP R&D $4.200–$4.435 billion $4.225–$4.465 billion Non-GAAP R&D(a) $3.725–$3.925 billion Unchanged GAAP
2023 Guidance
Prior Updated
GAAP R&D $4.200–$4.435 billion $4.225–$4.465 billion
Non-GAAP R&D(a) $3.725–$3.925 billion Unchanged
GAAP SG&A $2.460–$2.650 billion $2.490–$2.680 billion
Non-GAAP SG&A(a) $2.130–$2.280 billion Unchanged
GAAP gross margin on net product sales(d) 88%–90% 87%–89%
Non-GAAP gross margin on net product sales(a)(d) 90%–92% 89%–91%
COCM(e)* $720–$800 million $820–$880 million
Capital expenditures* $825–$950 million $800–$900 million
GAAP effective tax rate 10%–12% 8%–10%
Non-GAAP effective tax rate(a) 11%–13% 10%–12%
* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been or are expected to be recorded.

A reconciliation of full year 2023 GAAP to non-GAAP financial guidance is included below:

Projected Range
($ in millions) Low High
GAAP R&D $ 4,225 $ 4,465
Stock-based compensation expense 490 520
Acquisition-related integration costs 10 20
Non-GAAP R&D $ 3,725 $ 3,925
GAAP SG&A $ 2,490 $ 2,680
Stock-based compensation expense 310 330
Acquisition-related integration costs 50 70
Non-GAAP SG&A $ 2,130 $ 2,280
GAAP gross margin on net product sales 87 % 89 %
Stock-based compensation expense 1 % 1 %
Intangible asset amortization expense 1 % 1 %
Non-GAAP gross margin on net product sales 89 % 91 %
GAAP ETR 8 % 10 %
Income tax effect of GAAP to non-GAAP reconciling items 2 % 2 %
Non-GAAP ETR 10 % 12 %
Total
0
Shares
Related Posts